VCAM1 and hypertensive disorder: Our data showed that the Ang II-induced increases in serum VCAM-1 levels and SBP were dose-dependently reduced in mice administered the VCAM-1 neutralizing antibody (Figures 2A,B), indicating that the VCAM-1 neutralizing antibody effectively blocked VCAM-1 and inhibited hypertension in mice.